Skip to main content
Premium Trial:

Request an Annual Quote

Tm Bioscience Will Use Sirius Biomarkers to Develop Dx for Severe Sepsis

NEW YORK, March 20 (GenomeWeb News) - Tm Bioscience has exclusively licensed from Sirius Genomics certain patents for biomarkers linked to drugs used to treat severe sepsis.


Tm Bioscience will incorporate these markers into a diagnostic for use by critical-care physicians. The company said it expects to launch the test in the second half of 2007.


Tm said the test "could generate" more than $100 million in the first three years on the market.


Terms of the deal call for Tm Bioscience to provide Sirius an upfront payment of $4 million in two equal installments in the second and third quarters of this year. Sirius will repay this cash from earnings generated on the sale of the test. Tm and Sirius will share the remaining earnings equally over the term of the agreement.


The deal call covers a series of "possible mutations" that can occur in the genes associated with two proteins, protein C and arginine vasopressin.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.